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Abstract 
Introduction: The purpose of this study was to examine whether the combination of atypical and typical antipsychotic medications is re-
lated with metabolism and cognitive functions in the same manner and degree as taking medications of one kind only, i.e. atypical or typical. 
Material and methods: The participants of the study comprised of 91 adults with diagnosed mental illness (F-20-F69). The participants 
were divided into groups on the basis of the kind of administered medications: T+A (typical and atypical medications), A (atypical medications), 
T (typical medications), P (antidepressants, sedatives, normothymic/antiepileptic drugs). In the study, Short Test of Mental Status (STMS), 
Verbal Fluency Test (VFT), Rey Auditory Verbal Learning Test (RAVLT) were used for the purpose of examining cognitive functions. 
Results: The kind of antipsychotic medications taken by the patients did not differentiate the group in relation to BMI (p<0.13), 
nor in relation to the level of general cognitive function (p<0.72) or verbal fluency (p<0.34). Both atypical antipsychotic medications and 
the combination of atypical and typical medications were related to the occurrence of abdominal obesity (p<0.01). An increase  in waist 
circumference decreased an ability of abstract reasoning (p<0.005). When it comes to the body mass index, waist circu mference nega-
tively correlated with the delayed memory (p< 0.03, p<0.004). 
Discussion: Both the combination of atypical and typical antipsychotic medications and atypical medications are associated wi th 
the occurrence of abdominal obesity. The deposition of fat tissue in the abdomen negatively correlated with an ability to learn.  
Conclusions: The future studies might explain the interactions between antipsychotic medications, obesity and cognitive function. 
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Streszczenie 
Wstęp: Celem niniejszych badań było sprawdzenie czy kombinacja leków atypowych i typowych jest powiązana w takim samym 
stopniu z przemianą metaboliczną i funkcjami poznawczymi co leki z jednej grupy, to jest: atypowe, bądź typowe.  
Materiał i metoda: Do badań włączono 91 dorosłych z diagnozą zaburzeń psychicznych (F-20-F69). Uczestnicy zostali podzieleni na grupy 
w zależności od rodzajów przyjmowanych leków: T+A (leki typowe i atypowe), A (leki atypowe), T (leki typowe), P (antydepresanty, środki 
uspokajające, leki normotymiczne / leki przeciwpadaczkowe). Do diagnozy funkcji poznawczych użyto testów: STMS, VFT, RAVLT.  
Wyniki: Rodzaj przyjmowanych przez pacjentów leków nie różnicował grup pod względem BMI (p<0,13), ani też w odniesieniu do 
ogólnego poziomu funkcji poznawczych (p <0,72) i fluencji słownej (p <0,34). Zarówno leki przeciwpsychotyczne atypowe, jak i połączenie 
leków atypowych i typowych były związane z występowaniem otyłości brzusznej (p <0,01). Wzrost obwodu talii zmniejszał zdolność do 
myślenia abstrakcyjnego (p <0,005). Wskaźnik masy ciała, obwód talii korelował negatywnie z pamięcią odroczoną (p <0,03, p <0,004). 
Dyskusja: Zarówno kombinacja leków przeciwpsychotycznych atypowych i typowych jak i leki atypowe są związane z występowaniem 
otyłości brzusznej. Odkładanie się tkanki tłuszczowej w okolicy brzusznej koreluje negatywnie ze zdolnością do uczenia się.  
Konkluzje: Niewątpliwie niezbędne są przyszłe badania wyjaśniające interakcje między lekami przeciwpsychotycznymi, otyłością 
a funkcjami poznawczymi.  
 
Słowa kluczowe: przemiana metaboliczna, pamięć, myślenie abstrakcyjne.  
 
 
 
Introduction 
Overweight and obesity are one of the most important 
health problems in today's world. Growing food industry 
contributes to propagation of diets rich in fats and carbohy-
drates, and eating large portions of food [1]. According to the 
World Obesity Federation in the world, approximately 475 
million adults are obese and more than twice of this number 
are overweight, what indicates that more than 1.5 billion 
people worldwide has the wrong body mass [2]. 
There are several definitions of overweight and ob-
esity, which are largely based on the measurement of 
weight and height [3], and the most common is consi-
dered to be the one proposed by the World Health Organ-
ization (WHO). To determine obesity, it is necessary to 
calculate body mass index (BMI). This index is formed by 
dividing the body mass in kilograms by the square of the 
height specified in meters, (body mass (kg)/height (m2). 
According to this indicator, the overweight status is rec-
ognized for people with BMI ≥25.00 kg/m2, obesity from 
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BMI≥30.0 kg/m2, but underweight when the value of the 
index is less than 18.5 kg/m2 [4].  
Obesity brings with it a number of negative health 
consequences. Cardiovascular disease (mainly hyperten-
sion, heart disease and stroke), type 2 diabetes, diseases 
of the musculoskeletal system (e.g. osteoarthritis), and cer-
tain cancers (a.o. endometrial cancer, breast or colon cancer) 
are among the most potent risk factors of obesity [5].  
It should be emphasized that the accumulation of fat 
in the abdomen is strongly associated with the risk of 
developing cardiovascular disease [6]. The easiest way to 
diagnose obesity is to measure waist circumference [7]. 
Because there are differences within the correct diagnosis 
of body mass depending on age, gender and ethnicity. 
Several methods of abdominal obesity identification were 
proposed, but the most often used are those proposed by 
the National Cholesterol Education Program - Adult 
Treatment Panel III NCEP-ATP III) and the International 
Diabetes Federation (IDF) [8], [9]. According to the NCEP-
ATP III obesity is recognized when waist circumference in 
men is ≥102 cm and ≥88 cm in women. In contrast, ac-
cording to the IDF’s definition of abdominal obesity in 
white race, it is diagnosed when waist circumference is 
≥94 cm in men and in women ≥80 cm [10]. 
Persons suffering from mental disorders, including 
psychotic disorders, have greater tendency to have in-
creased body mass [11]. Propensity for psychosis is influ-
enced by several factors, including: specific diet and life-
style, smoking and the effects of some psychotropic medi-
cations that cause mass gain [12]. The influence of the 
various medications on the body mass gain is varied. The 
largest increase is observed after the use of atypical anti-
psychotics medications, so-called new-generation, partic-
ularly such as clozapine and olanzapine. In terms of atypi-
cal antipsychotics medications, only those from the 
groups of molindone, ziprasidone, and aripiprazole do not 
cause mass gain. However, in the case of conventional medi-
cations, so-called first-generation antipsychotics, only those 
from the group of chlorpromazine cause mass gain [13].  
It should be noted that the tendency to increased 
body mass was observed in psychiatric patients before 
taking antipsychotic treatment [14]. It is emphasized that 
there is a genetic predisposition of the mentally ill pa-
tients to excessive accumulation of body fat [15]. Obesity 
is strongly associated with cognitive impairment, which 
with age may lead to the formation of dementia [16]. 
Obesity can affect mental functions by changing plasticity 
of the brain, what may contribute to the development of 
cognitive and mood disorders [17].  
In the present study, we attempted to examine the 
relationship between the cognitive impairment and the 
increased body mass, taking into account the types of the 
antipsychotics medications taken by the respondents. 
 
Material and methods 
We recruited 91 persons with mental disorders, partici-
pants of the Communal Home of Mutual Aid, the Occupational 
Therapy Workshops and the staff of the District Vocational 
Rehabilitation Facility. Among the group, there were 48 people 
with schizophrenia (F-20), 3 with schizoaffective disorders 
(F25), 3 with persistent delusional disorder (F22), 7 with 
affective bipolar disorder (F31), 6 with depression (F32), 13 
with neurotic disorders associated with stress and somato-
form disorders (F40-F48), 11 with personality disorders and 
adult behavior disorder (F60-F69). Each person had to sign a 
voluntary consent to participate in research in accordance with 
resolution of the Medical University of Lublin Bioethics Com-
mittee (No KE-0254/101/ 2013). 
 The study consisted of two stages:  
(1) Physical examination: Height, weight, waist cir-
cumference, hip circumference, calculation of BMI and 
abdominal obesity diagnosis according to the clinical IDF 
guidelines, clinical interview with the tested person con-
cerning his/her career (co-existing diseases, medications, 
number of hospitalizations); 
(2)  Psychological tests: in order to diagnose cogni-
tive functions. They were assessed using: 
 a Short Test of Mental Status (STMS), used to 
measure cognitive functions, consisting of test of orienta-
tion trials (allo and autopsychic orientation), attention, 
learning, calculation, abstract reasoning, messages, draw-
ings (constructional praxis), recall, 
  Verbal Fluency Test (VFT), to examine the ver-
bal semantic and categorical fluency, 
  Rey Auditory Verbal Learning Test (RAVLT ) – 
to assess short term memory, direct and delayed memory.  
 
Description of the group 
The study involved 91 participants (including 51 wom-
en and 40 men, mean age of patients was 46 years, the stan-
dard deviation +/-13,3 years). The group consisted of per-
sons who were currently under constant psychiatric care. 
The exclusion criteria were: (1) substance abuse or depen-
dence (2) a history of neurologic disorders (3) serious or 
unstable medical condition (i.e. poorly controlled hyperten-
sion, diabetes or coronary artery disease). 
Because of the variety of taken medications, partici-
pants were divided into several groups according to defining 
features shown in Table 1. The largest group of participants 
(34%) were receiving atypical antipsychotics medication 
(known as second generation antipsychotics), usually olan-
zapine, clozapine, amisulpride, risperidone, quetiapine, and 
sertindole, when it comes to 14% of participants, they were 
receiving typical antipsychotic medications (known as first 
generation antipsychotics), usually perazinum, haloperidol, 
while the other group (30%) was taking both typical and 
atypical antipsychotic medications. The remaining 21% of 
participants were taking other medicines: antidepressants, 
sedatives, sleeping pills normothymic/antiepileptic. 
 
Statistical analysis 
The obtained results were statistically analyzed us-
ing STATISTICA software, version 10. 
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Because of the lack of normality distribution of several 
variables, the study correlation between variables was carried 
out using a correlation coefficient of Spearman’s rank. Due to 
the lack of normality distribution, testing hypotheses were 
performed using Mann-Whitney U test (comparing 2 groups). 
An analysis of the differences in the individual parameters was 
carried out using a Kruskal-Wallis test for independent trials, 
taking into account post hoc analysis (Dunn’s Test). The results 
are shown in the charts using the median. The results were 
found to be significant at the level of p<0.05.  
 
Results 
Overweight and obesity 
Among all the investigated, overweight was found in 
32 people (35%), while in 27 (30%) persons the correct  
 
 
 
 
Figure 1. The BMI index and abdominal obesity according to the IDF guidelines in the group of women and men as meas-
ured in percentages. 
 
Figure 2.The body mass and the type of taken medications.             Figure 3. The waist circumference and the type of taken medications 
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Figure 4. The BMI and the type of taken medications 
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body mass was found (Figure 1.). Obesity class I was diagnosed 
in 26 patients (28%), and obesity class II in 5 (5%). One person 
was underweight (2%). Abdominal obesity, according to IDF 
guidelines, was diagnosed in 70% of patients. 
 
Psychotropic medications vs. overweight and obesity 
The statistical analysis showed that the type of medica-
tions was associated with body mass, p<0.03, (Figure 2.). 
However, post hoc analysis indicated only the existence of 
certain tendency, particularly that people who did not 
take typical and atypical antipsychotics medicines (P) had 
lower body mass than persons taking both typical and 
atypical medications (T+A). Although, this tendency did 
not reach a level of statistical significance (p<0.08). 
It has been noticed that the type of taken medications 
was also associated with the waist circumference, p<0.01, 
(Figure 3.). Post hoc analysis showed that persons who were 
not taking typical and atypical antipsychotics medications (P) 
had lower waist circumference than persons taking atypical 
antipsychotics medications (A), (p<0.04) and typical and atypi-
cal antipsychotics medications (T+A), (p<0.02). Medians were, 
respectively: 87 (P), 93 (T), 101 (T+A), 102 (A). It was also 
found that BMI did not differ significantly in the various work-
ing groups, p<0.13, (Figure 4.). 
 
Overweight and obesity, and cognitive functions 
Table 2. shows the correlations of Spearman’s ranks 
between body mass indexes and waist circumference, and 
cognitive functions having regard to all the patients. The 
negative correlations were observed between several 
variables: age of patients and abstract thinking (rs -0.22, 
p<0.03), age and direct memory (rs -0.23, p<0.02), age of 
patients and delayed memory (rs -0.29, p<0.005). 
Body mass also showed a negative relationship with the 
memory, but only with the delayed one (rs -0.27, p<0.005). The 
body mass index, waist circumference correlated with the 
memory. In the case of the first variable, a relationship with the 
delayed memory was observed ( rs -0.23, p<0.03), in the case 
of the other two, both with the direct and delayed ones (rs -
0.22, p<0.03), (rs -0.36, p<0.004). 
It has been shown that an increase in waist circumfe-
rence measured in centimeters was connected with a de-
creased ability to abstract reasoning (rs -0.29, p<0.005). 
It should be noted, that overall cognitive functions, 
which are the sum of all the subtests of STMS and the re-
sults in the VFT and RAVLT tests showed no statistically 
significant relationship. 
In addition, it was shown that people with abdominal 
obesity did worse in the test measuring the delayed memo-
ry (p<0.04). 
In order to investigate the impact of BMI on cogni-
tive function, statistical analyses were made in three 
groups: overweight (n = 32), obesity class I (n = 26), cor-
rect BMI (n = 27). Because of the small number of persons 
with obesity class II (n = 5) and underweight (n = 1), they 
were were excluded. Analysis by means of Kruskal-Wallis 
test did not reveal any statistically significant differences 
between the BMI and cognitive functions in different 
groups (p>0.05). 
 
Discussion 
Persons suffering from mental disorders have greater 
tendency to overweight and obesity, what is caused by a num-
ber of factors, in particular, specific lifestyle and the negative 
effects of the antipsychotic treatment. As shown by studies of 
not yet treated patients, some diseases such as schizophrenia 
are closely associated with genetic predispositions to excessive 
depositing the adipose tissue [18], [19], [20], [21].   
It shall be considered that 1 of 2 patients with schi-
zophrenia is overweight [22]. As many as 68% of people 
treated for affective bipolar disease is overweight or ob-
ese and approximately 58% of people with heavier de-
pression has obesity class I (BMI≥30) [23]. In the own 
study, 68% of the total tested were overweight and ob-
ese,, and obesity was found in 32% of them.   
There are several extensive studies checking the effects 
of antipsychotic, typical and atypical medications on body 
mass indexes. It is assumed that atypical medicines have a 
greater impact on body mass gain than typical medication [24].  
In the group of 42,437 patients suffering from a va-
riety of mental illnesses, it was shown that both typical 
and atypical medications can affect body mass gain. Inte-
restingly, no statistically significant difference between 
them was observed [25]. In our study, it was shown that 
prescribed antipsychotics medications were related to 
body mass gain, but no significant differences between the 
various types of medications were observed. 
Body mass gain in persons suffering from mental ill-
ness is associated with the use of psychotropic medications, 
with impaired sense of satiety, metabolic disorder and specif-
ic less active lifestyle. These factors affect the growth of fatty 
tissues in the abdomen, that is why patients taking atypical 
drugs are more exposed to abdominal obesity than persons 
taking typical medications [13].  
The existing scientific reports indicate that persons 
with mental disorders, particularly suffering from schizoph-
renia, schizoaffective disorders, mood disorders, single and 
bipolar disorders, have greater tendency to deposit fat tissue 
in the abdominal area, and this tendency is further enhanced 
with antipsychotic medications [14], [26].  
Statistical analysis showed that the atypical medica-
tion and combination of typical and atypical medication 
were related to the increase in waist circumference. It 
should be noted that, in relation to BMI, there were no 
differences between the particular groups. It follows from 
this that antipsychotic medicines may lead to a deposit of 
the particularly harmful fat abdomen, what contributes to 
the creation of cardiovascular diseases. Probably, more 
accurate taking into account lifestyle and health habits of 
patients, would give a fuller picture of this phenomenon. 
The previous studies show, that atypical medica-
tions contribute to a significant improvement of cognitive 
function, in contrast to typical medications, which usually 
lead to deterioration of cognitive abilities [27], [28], [29].  
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Table 1. Groups divided by the types of taken medications.  
Division Type of taken medications Sample percentage 
T+A Typical and atypical antipsychotic medications 27 (30%) 
 T Typical antipsychotic medications 14 (15%) 
A Atypical antipsychotic medications 31 (34%) 
 P 
Other medicines: antidepressants, sedatives, sleeping pills 
normothymic/antiepileptic 19 (21%) 
 
Table 2. Correlation of Spearman’s ranks between the BMI index, body mass, waist circumference and cognitive functions 
for all responders* - marked coordinates of correlation are significant at p <0.05.  
 N - Important R - Spearman p 
* Age & Abstract reasoning STMS 91 -0.2216 0.0347 
* Age & Direct Recall  91 -0.2339 0.0256 
*Age & Delayed Recall  91 -0.2872 0.0057 
*Body mass & Delayed Recall  91 -0.2719 0.0091 
*BMI & Delayed Recall  91 -0.2261 0.0311 
*Waist Circumference & Abstract reasoning 
STMS 
91 -0.2883 0.0055 
*Waist Circumference & Direct Recall  91 -0.2248 0.0320 
*Waist Circumference & Delayed Recall  91 -0.3591 0.0004 
 
It is important to note that not only medicines affect 
the cognitive functions, but also the type of disorder is in 
this respect important. Psychotic mental disorders most 
seriously affect the deterioration in cognitive functions 
and these dependencies are becoming worse, especially 
with age, what refers to such diseases as schizophrenia or 
schizoaffective disorders [30], [31].  
Many scientific reports indicate that obesity is a fac-
tor that leads to neurocognitive disorders [32], [33] and 
the latest results of the survey show that obesity leads to 
neurodegenerative diseases based on interferences in the 
white matter of the brain [34], [35], [36], [37], [38]. Re-
search carried out on mice suggest that obesity leads to 
hippocampus function disorders, the structure responsi-
ble, inter alia, for learning and ability to learn [39].  
Examining the relationship between cognitive func-
tions and obesity in individuals with mental illness, the 
majority of correlations were detected in relation to 
memory processes. It was observed that both the increase 
in BMI, body mass and waist circumference negatively 
correlated with the delayed auditory memory and these 
dependencies increased along with the age of patients. 
This is in line with other test results. Gunstad and 
co., in the group of 1703 people without mental disorders, 
demonstrated that abdominal obesity leads to cognitive 
impairment, including the disturbance of memory. The 
team noted that the increased mass leads to abnormalities 
in the verbal fluency and attentions, however such depen-
dencies were not observed in the own study [32].  
Spitznagel et al., in the group of 84 persons un-
derwent bariatric surgery treatments and the assess-
ment of cognitive functions before and after the sur-
gery demonstrated that short-term memory is improv-
ing along with reduction in weight [40], what confirms 
the claim that obesity is closely linked with the deteri-
oration of cognitive functions, but this process is to 
certain extent reversible.  
By analyzing the study group, the relationship be-
tween abdominal obesity and the ability to abstract rea-
soning was observed, and these dependencies increased 
along with age and thus, with the duration of the disease. 
It should be noted that in most mental diseases, particu-
larly those of psychotic ground, it comes to the deteriora-
tion of overall cognitive functions [41]. Abstract reasoning 
plays in this particular role, as according to some research-
ers, it is distorted in people with the first, untreated episode 
of the disease, next to learning capacity and attention [42].  
By analyzing the study group, it should be noted that 
cognitive functions such as auditory memory, especially 
the delayed one and abstract reasoning, which showed 
the first relations with obesity, are first symptoms of 
dementia changes. According to recent scientific reports, 
obesity and changes caused by it lead to dementia vascu-
lar disorders and Alzheimer's disease [43].  
The presented own research is not free from limita-
tions. The group tested by us is diverse in terms of the 
type of disturbance and taken types of medications as well 
as their doses. Most of the research in this area does not 
take into account knowledge of patients on the subject 
and, consequently, the lifestyle of the patients. There is a 
need for research on a wider range taking into account 
these variables. 
 
Conclusions  
The implementation of atypical and combination of 
typical and atypical medications are associated with the 
occurrence of abdominal obesity, which carries with it a 
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number of negative consequences such as cardiovascular 
disease, and diabetes type 2. Obesity correlates with wor-
sening of cognitive functioning, particularly, in the area of 
memory and abstract reasoning. It was observed that 
both the increase in BMI, body mass and waist circumfe-
rence are negatively related to auditory delayed memory 
and these dependencies intensify along with age of pa-
tients. Future studies are needed in this area. 
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